Baer Maria R
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Curr Oncol Rep. 2002 Sep;4(5):398-402. doi: 10.1007/s11912-002-0033-z.
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patients, and multiparameter flow cytometry, which has broader applicability. Although significant advances have been made in the development of assays for monitoring residual disease, and particularly in techniques for molecular quantitation, additional refinement and validation are needed before these assays can be applied routinely in clinical management.
急性髓系白血病（AML）是一种可治愈的恶性肿瘤，但其治愈率仍然低得令人失望。准确量化残留的AML细胞将使治疗个体化，从而提高每位患者的治愈可能性。正在研究用于检测残留疾病的技术包括针对AML患者亚群中存在的异常的分子检测，以及具有更广泛适用性的多参数流式细胞术。尽管在监测残留疾病的检测方法开发方面取得了重大进展，尤其是在分子定量技术方面，但在这些检测方法能够常规应用于临床管理之前，还需要进一步完善和验证。
